Welcome to
WraSer Pharmaceuticals
WraSer Pharmaceuticals is an independent specialty pharmaceutical marketing and distribution company providing niche branded prescription products to physicians, pharmacies and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.
our mission
Our vision is to be a premier pharmaceutical company providing the most responsive, innovative, financially sound medicines through quality customer service and education.
FEATURED PRODUCTS
WARNING: BLEEDING RISK
See full prescribing information for complete boxed warning.
- Do not use ZONTIVITY in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH); or active pathological bleeding. (4.1, 4.2)
- Antiplatelet agents, including ZONTIVITY, increase the risk of bleeding, including ICH and fatal bleeding. (5.1)
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYME; HEPATOTOXICITY and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS.
CETRAXAL
CETRAXAL (ciprofloxacin otic solution) 0.2% contains the synthetic antimicrobial agent ciprofloxacin hydrochloride. CETRAXAL (ciprofloxacin otic solution) is a sterile, preservative-free solution for otic use. Each single use container of CETRAXAL delivers 0.25 mL of solution equivalent to 0.5 mg of ciprofloxacin.
OTOVEL
OTOVEL® (ciprofloxacin and fluocinolone acetonide) is used in children 6 months of age and older, who have a tiny cylinder tube in their eardrum known as a tympanostomy tube to prevent excess fluid in the middle ear. Otovel is used to treat a type of middle ear infection called acute otitis media with tympanostomy tubes (AOMT) caused by certain bacteria.
PHARMA news
Stay up to date with the latest Pharmaceutical industry news & articles.
![RSS]()
Article List RSS
- Stealth Company Ausel Cancer Innovation begins enrollment of patients for final clinical study
- Nevro Announces Acquisition of Vyrsa™ Technologies
- First patient with metastatic prostate cancer to receive 2 doses of Cu-67 SAR-bisPSMA achieves undetectable PSA level
- Acclinate Collaborates with Merck to Increase Clinical Trial Diversity
- Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer